The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019.
This report provides:
An overview of the global market for drug-device combinations.
Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental restorative materials, biologic wound care products such as collagen-based dressings as therapeutic agents for wound healing, drug-device combination products for ocular applications, and photodynamic therapy.
Detailed patent analysis and research and development updates.
Comprehensive company profiles of major players.
SCOPE AND FORMAT
In preparing this report, an overall study of the drug-device combination market was undertaken.
The report covers the following product categories:
Drug-eluting stents (DES).
Drug-eluting beads (DEB).
Antibiotic-loaded bone cements.
Glass ionomer cements.
Bone graft substitutes.
Antibacterial-releasing dental restorative materials.
Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
Drug-device combination products for ocular applications.
Many nanotechnology applications.
Devices that do not combine a drug with the delivery mechanism are not covered; for example, insulin pumps are not covered.
Related areas, such as drug delivery systems and nanotechnology, were key to the analysis as well, as these newer areas such as nanotechnology foreshadow likely product developments in the years ahead. All major aspects of the drug-device combination market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory involvement. Participating companies are discussed in light of technological strengths and weakness, relative market share, marketing strengths, and innovative marketing practices. Included is a detailed discussion of the current regulatory environment for drug-device combination products and how it is affecting development and approval of such products.